RAPGEF4 and cardiac arrhythmia: Unfortunately, the practical use of S-220 in vivo is limited, since activation of EPAC2, but not EPAC1, causes arrhythmia and reduced cardiac function in animal models [69,70] and moreover, 007 has limited cell permeability and potency in vivo.